News >

Regorafenib/Nivolumab Combo to Be Explored in Phase III MSS CRC Trial

Gina Columbus @ginacolumbusonc
Published: Thursday, Jul 18, 2019

Scott Z. Fields, MD

Scott Z. Fields, MD
The combination of regorafenib (Stivarga) and nivolumab (Opdivo) will be compared with regorafenib alone in a phase III trial of patients with microsatellite stable (MSS) colorectal cancer (CRC), following encouraging phase Ib findings of the REGONIVO study.1

Further biomarker analyses are ongoing for the study.

References

  1. Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter into a Clinical Collaboration Agreement to Investigate Stivarga (Regorafenib) and Opdivo (Nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer. Bayer. Published July 18, 2019. https://bit.ly/2SnCeyX. Accessed July 18, 2019.
  2. Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol. 2019;37(suppl; abstr 2522). doi: 10.1200/JCO.2019.37.15_suppl.2522.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x